ULTIO fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Ultimovacs AS operates as a pharmaceutical company. The firm engages in the development of novel immunotherapies against cancer. Its product, UV1, is a therapeutic cancer vaccine that activates the immune system to recognize telomerase. The company was founded on January 26, 2011 and is headquartered in Oslo, Norway.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
ULTIO does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company